Prostaglandins (PGs) are powerful lipid mediators in
many physiological
and pathophysiological responses. They are produced by oxidation of
arachidonic acid (AA) by cyclooxygenases (COX-1 and COX-2) followed
by metabolism of endoperoxide intermediates by terminal PG synthases.
PG biosynthesis is inhibited by nonsteroidal anti-inflammatory drugs
(NSAIDs). Specific inhibition of COX-2 has been extensively investigated,
but relatively few COX-1-selective inhibitors have been described.
Recent reports of a possible contribution of COX-1 in analgesia, neuroinflammation,
or carcinogenesis suggest that COX-1 is a potential therapeutic target.
We designed, synthesized, and evaluated a series of (E)-2′-des-methyl-sulindac sulfide (E-DMSS) analogues for inhibition of COX-1. Several potent
and selective inhibitors were discovered, and the most promising compounds
were active against COX-1 in intact ovarian carcinoma cells (OVCAR-3).
The compounds inhibited tumor cell proliferation but only at concentrations
>100-fold higher than the concentrations that inhibit COX-1 activity. E-DMSS analogues may be useful probes of COX-1 biology in
vivo and promising leads for COX-1-targeted therapeutic agents.